tbuckley/cabot-search huggingface dataset:
Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)
Authors: Mohamad Mohty, Myriam Labopin, Noel-Jean Milpied, Jan J. Cornelissen, Didier Blaise, Eefke Petersen, Niklas Theorin, Hakan Goker, Gerard Socie, Vanderson Rocha
Journal: Blood (2008)
Hematopoiesis of Human Induced Pluripotent Stem Cells Derived From Blood Cells of Healthy Donors and Patients with the JAK2-V617F Somatic Mutation.
Authors: Zhaohui Ye, Huichun Zhan, Prashant Mali, Sarah Dowey, Donna Williams, Yoon-Young Jang, Chi Van Dang, Jerry L. Spivak, Alison R Moliterno, Linzhao Cheng
Journal: Blood (2009)
Re-Targeting of an NK Cell Line (NK92) with Specificity for CD19 Efficiently Kills Human B-Precursor Leukemia Cells.
Authors: Annette Romanski, Christoph Uherek, Gesine Bug, Tina Muller, Claudia Rossig, Manuela Kampfmann, Nicola Krossok, Dieter Hoelzer, Erhard Seifried, Winfried Wels, Oliver G. Ottmann, Torsten Tonn
Journal: Blood (2004)
Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure
Authors: Mateusz Sokolski, Robert Zymliński, Jan Biegus, Paweł Siwołowski, Sylwia Nawrocka‐Millward, John Todd, Malli Rama Yerramilli, Joel Estis, Ewa Anita Jankowska, Waldemar Banasiak, Piotr Ponikowski
Journal: European Journal of Heart Failure (2017)
Augmented Reality Takes Parkinson Disease Dance Therapy Out of the Classroom
Authors: Jennifer Abbasi
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rituximab Improves the Outcome of Upfront Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: A Comparison of Different Strategies.
Authors: Michael Rieger, Mathias Witzens-Harig, Manfred Hensel, Baerbel Seyfarth, Maike Nickelsen, Michael Kneba, Norbert Schmitz, Anthony D. Ho, Peter Dreger
Journal: Blood (2007)
Bedside Contribution of Electrical Impedance Tomography to Setting Positive End-Expiratory Pressure for Extracorporeal Membrane Oxygenation–treated Patients with Severe Acute Respiratory Distress Syndrome
Authors: Guillaume Franchineau, Nicolas Bréchot, Guillaume Lebreton, Guillaume Hekimian, Ania Nieszkowska, Jean-Louis Trouillet, Pascal Leprince, Jean Chastre, Charles-Edouard Luyt, Alain Combes, Matthieu Schmidt
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Optimal positive end-expiratory pressure (PEEP) is unknown in patients with severe acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation receiving mechanical ventilation with very low tidal volume.To evaluate the ability of electrical impedance tomography (EIT) to monitor a PEEP trial and to derive from EIT the best compromise PEEP in this setting.A decremental PEEP trial (20-0 cm H2O) in 5 cm H2O steps was monitored by EIT, with lung images divided into four ventral-to-dorsal horizontal regions of interest. The EIT-based PEEP providing the best compromise between overdistention and collapsed zones was arbitrarily defined as the lowest pressure able to limit EIT-assessed collapse to less than or equal to 15% with the least overdistention. Driving pressure was maintained constant at 14 cm H2O in pressure controlled mode.Tidal volume, static compliance, tidal impedance variation, end-expiratory lung impedance, and their respective regional distributions were visualized at each PEEP level in 15 patients on extracorporeal membrane oxygenation. Low tidal volume (2.9-4 ml/kg ideal body weight) and poor compliance (12.1-18.7 ml/cm H2O) were noted, with significantly higher tidal volume and compliance at PEEP10 and PEEP5 than PEEP20. EIT-based best compromise PEEPs were 15, 10, and 5 cm H2O for seven, six, and two patients, respectively, whereas PEEP20 and PEEP0 were never selected.The broad variability in optimal PEEP observed in these patients with severe ARDS under extracorporeal membrane oxygenation reinforces the need for personalized titration of ventilation settings. EIT may be an interesting noninvasive bedside tool to provide real-time monitoring of the PEEP impact in these patients.
Cholecystitis/cholangitis secondary to drainage of the biliary tree into an obstructed duodenum: a new technique with a novel complication?
Authors: Travis Ackermann, Simon Hew, Paul Cashin, Michael Swan, Daniel Croagh
Journal: Endoscopy (2017)

A previously well, 73-year-old woman presented with chest pain and was noted to have markedly abnormal cholestatic liver function tests. Magnetic resonance cholangiopancreatography (MRCP) demonstrated a multicystic mass in the pancreatic head with possible extrinsic biliary compression. She underwent endoscopic ultrasound (EUS) with cytological aspiration, which demonstrated dysplastic cellular material.
Long-term (potential 10-year follow-up) toxicity after treatment for prostate cancer with either external beam radiation therapy, interstitial brachytherapy, or radical prostatectomy.
Authors: G. K. Hunter, C. A. Reddy, K. Angermeier, J. Ulchaker, K. L. Stephans, R. D. Tendulkar, C. Zippe, P. Kupelian, E. A. Klein, J. P. Ciezki
Journal: Journal of Clinical Oncology (2011)

65 Background: To examine gastrointestinal (GI) and genitourinary (GU) toxicity profiles of patients treated in 1999 with external beam radiotherapy (RT), prostate interstitial brachytherapy (PI) or radical prostatectomy (RP). Methods: The records of 483 patients treated in 1999 were retrospectively reviewed to evaluate toxicity profiles, with 24% of the patients treated with PI, 40% with RP, and 36% with RT. Late GI and GU morbidity profiles were specifically examined and both were graded according to the RTOG acute and late morbidity scoring criteria. Other factors examined were patient age, BMI, smoking history, and medical comorbidities including presence of diabetes mellitus (DM), peripheral vascular disease, and connective tissue disease. Due to the low event rate for late GU and GI toxicities, a competing risk regression (CRR) analysis was done with death as the competing event. Results: See Table. Median follow-up time was 8.6 years (range 0.2-11.5). On CRR univariate analysis the presence of DM was associated with GU toxicity grade ≥2 (p=0.043, HR 2.35, 95% CI=1.03-5.39). DM remained significant on multivariate analysis (p=0.034, HR 2.44, 95% CI= 1.07-5.59). Since there were no events in the RP group, only the PI and RT patients were included in the CRR analysis for late GI toxicity Grade &lt;=2. On univariate analysis, RT and DM were significantly associated with late GI toxicity. On multivariable analysis, both variables remained significant (RT: p=0.038, HR=4.71, 95%CI=1.09-20.3; DM: p=0.008, HR=3.81, 95%CI=1.42-10.2). Conclusions: Late effects occur with all three treatment modalities. The presence of DM at the time of treatment was significantly associated with worse late GI and GU toxicity. RT was significantly associated with worse late GI toxicity compared to PI and RP. [Table: see text] No significant financial relationships to disclose.
Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Andrew R. Rezvani, L. Norasetthada, T. Gooley, Mohamed Sorror, Stephen J. Forman, Edward Agura, T. Chauncey, Richard T. Maziarz, Michael Maris, J. Shizuru, B. Bruno, James C. Wade, T. Lange, Andrew Yeager, Brenda M. Sandmaier, Rainer F. Storb, David G. Maloney
Journal: Blood (2007)
Silvestrol Modulates Direct Anti-Tumor Activity Against Epstein-Barr Virus (EBV)-Associated Lymphomas While Sparing Innate and Antigen Specific Adaptive Immunity
Authors: John T. Patton, Mark E Lustberg, Sabrina L Garman, A Douglas Kinghorn, Li Pan, David M. Lucas, Michael R. Grever, Robert A. Baiocchi
Journal: Blood (2011)
Prognostic impact of the CD34+/CD38− cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation
Authors: Madlen Jentzsch, Marius Bill, Deedra Nicolet, Sabine Leiblein, Karoline Schubert, Martina Pless, Ulrike Bergmann, Kathrin Wildenberger, Luba Schuhmann, Michael Cross, Wolfram Pönisch, Georg‐Nikolaus Franke, Vladan Vucinic, Thoralf Lange, Gerhard Behre, Krzysztof Mrózek, Clara D. Bloomfield, Dietger Niederwieser, Sebastian Schwind
Journal: American Journal of Hematology (2017)

Abstract In acute myeloid leukemia (AML), leukemia‐initiating cells exist within the CD34+/CD38− cell compartment. They are assumed to be more resistant to chemotherapy, enriched in minimal residual disease cell populations, and responsible for relapse. Here we evaluated clinical and biological associations and the prognostic impact of a high diagnostic CD34+/CD38− cell burden in 169 AML patients receiving an allogeneic stem cell transplantation in complete remission. Here, the therapeutic approach is mainly based on immunological graft‐versus‐leukemia effects. Percentage of bone marrow CD34+/CD38− cell burden at diagnosis was measured using flow cytometry and was highly variable (median 0.5%, range 0%–89% of all mononuclear cells). A high CD34+/CD38− cell burden at diagnosis associated with worse genetic risk and secondary AML. Patients with a high CD34+/CD38− cell burden had shorter relapse‐free and overall survival which may be mediated by residual leukemia‐initiating cells in the CD34+/CD38− cell population, escaping the graft‐versus‐leukemia effect after allogeneic transplantation. Evaluating the CD34+/CD38− cell burden at diagnosis may help to identify patients at high risk of relapse after allogeneic transplantation. Further studies to understand leukemia‐initiating cell biology and develop targeting therapies to improve outcomes of AML patients are needed.
STEM-11MECHANISMS OF CDC20-ANAPHASE-PROMOTING COMPLEX ACTION IN HUMAN GLIOBLASTOMA STEM-LIKE CELLS
Authors: Amit Gujar, Tatenda Mahlokozera, Diane Mao, Yanchun Pan, Hiroko Yano, Albert Kim
Journal: Neuro-Oncology (2015)

Recent studies have shown that the major mitotic regulator CDC20-Anaphase Promoting Complex (APC) is required for the maintenance of human glioblastoma stem-like cells (GSCs), a clinically important subpopulation of glioblastoma cells that are believed to underlie tumor recurrence. We have previously shown that CDC20-APC operates through pluripotency transcription factor SOX2 to promote GSC self-renewal and invasion in vitro (Mao, Gujar et al. Cell Reports. 2015). Using patient-derived GSCs, we herein show that APC co-activator CDC20 is required for GSC tumorigenicity in an orthotopic xenograft model. We further demonstrate through in vivo epistasis experiments that CDC20 acts through SOX2 to control GSC tumorigenicity. To test if CDC20-APC activity might dictate GSC responsiveness to standard-of-care chemotherapy agent temozolomide (TMZ), we utilized pharmacological and genetic approaches to inhibit CDC20-APC activity. Intriguingly, both APC inhibitor ProTAME and lentiviral CDC20 RNA interference augmented TMZ cytotoxicity in human GSCs. Collectively, these data suggest that CDC20-APC controls the tumor-initiating potential of GSCs in vivo through SOX2 and that CDC20-APC inhibitory strategies may not only disrupt the GSC state but also enhance the efficacy of chemotherapy.
A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure
Authors: Aziz Nazha, Rami S. Komrokji, Guillermo Garcia-Manero, John Barnard, Katrina Zell, Cassie Zimmerman, Najla H. Al Ali, Gail J Roboz, David P. Steensma, Amy E. DeZern, Eric Padron, Elias J. Jabbour, Molly Dara Greenberg, Alan F. List, Hagop M. Kantarjian, Jaroslaw P. Maciejewski, Mikkael A. Sekeres
Journal: Blood (2015)
HMGA1 Drives Inflammatory Pathways, Cell Cycle Progression, and Embryonic Stem Cell Genes During Leukemic Transformation
Authors: Andrew Schuldenfrei, Amy Belton, Jeanne Kowalski, C. Conover Talbot, Francescopaolo Di Cello, Weijie Poh, Hua-Ling Tsai, Sandeep N Shah, Tait Huso, David Huso, Linda Resar
Journal: Blood (2011)
ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier
Authors: R. Dal Magro, F. Ornaghi, I. Cambianica, S. Beretta, F. Re, C. Musicanti, R. Rigolio, E. Donzelli, A. Canta, E. Ballarini, G. Cavaletti, P. Gasco, G. Sancini
Journal: Journal of Controlled Release (2017)
Regional astrocyte IFN signaling restricts pathogenesis during neurotropic viral infection
Authors: Brian P. Daniels, Harsha Jujjavarapu, Douglas M. Durrant, Jessica L. Williams, Richard R. Green, James P. White, Helen M. Lazear, Michael Gale, Michael S. Diamond, Robyn S. Klein
Journal: Journal of Clinical Investigation (2017)

Type I IFNs promote cellular responses to viruses, and IFN receptor (IFNAR) signaling regulates the responses of endothelial cells of the blood-brain barrier (BBB) during neurotropic viral infection. However, the role of astrocytes in innate immune responses of the BBB during viral infection of the CNS remains to be fully elucidated. Here, we have demonstrated that type I IFNAR signaling in astrocytes regulates BBB permeability and protects the cerebellum from infection and immunopathology. Mice with astrocyte-specific loss of IFNAR signaling showed decreased survival after West Nile virus infection. Accelerated mortality was not due to expanded viral tropism or increased replication. Rather, viral entry increased specifically in the hindbrain of IFNAR-deficient mice, suggesting that IFNAR signaling critically regulates BBB permeability in this brain region. Pattern recognition receptors and IFN-stimulated genes had higher basal and IFN-induced expression in human and mouse cerebellar astrocytes than did cerebral cortical astrocytes, suggesting that IFNAR signaling has brain region-specific roles in CNS immune responses. Taken together, our data identify cerebellar astrocytes as key responders to viral infection and highlight the existence of distinct innate immune programs in astrocytes from evolutionarily disparate regions of the CNS.
Impaired Hematopoietic Differentiation of iPSCs Derived From Patients with FPD/AML
Authors: Masatoshi Sakurai, Hiroyoshi Kunimoto, Naohide Watanabe, Yumi Fukuchi, Ken Sadahira, Shinsuke Yuasa, Keiichi Fukuda, Satoshi Yamazaki, Hiromitsu Nakauchi, Yasuhiro Ebihara, Kohichiro Tsuji, Etsuro Ito, Yuka Harada, Hironori Harada, Shinichiro Okamoto, Hideaki Nakajima
Journal: Blood (2012)
Action of SDF-1/CXCR4 axis in liver metastasis of colorectal cancer.
Authors: Shinichiro Yamada, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Hiroki Mori, Jun Hanaoka, Yu Saito, Michihito Asanoma, Hidenori Miyake
Journal: Journal of Clinical Oncology (2012)

530 Background: It has recently been suggested that the SDF-1/CXCR4 axis is involved in tumor progression, angiogenesis, metastasis, and survival in various cancer. In this study, we investigate the possible role of SDF-1/CXCR4 axis in colorectal liver metastasis. Methods: Both primary colorectal tumors and liver metastatic tumors were obtained from 12 patients with colorectal liver metastasis. Expression levels of CXCR4 and SDF-1 were determined using RT-PCR. In 4 patients with benign liver disease, the expression level of SDF-1 in normal liver tissues was also determined. We divided the 12 patients into two groups; high expression group (n=6) and low expression group (n=6) according to each expression level of SDF-1 and CXCR4, and compared the clinicopathological factors between the two groups. Results: 1. CXCR4 expression levels in primary tumor: The frequency of the peritoneal dissemination in the CXCR4 high expression group was higher than in the low expression group (p=0.07). Moreover, overall survival rate in the CXCR4 high expression group was significantly lower than that in the low expression group (3 year-survival rate: 67% vs. 100%, p&lt;0.05). 2. CXCR4 in metastatic tumor tissues and SDF-1 in non-tumor liver tissues: The expression level of SDF-1 in non-tumor liver tissues was significantly higher than that in normal liver tissues (p&lt;0.01). A significant correlation between the CXCR4 expression levels in metastatic tumor tissues and SDF-1 expression levels of non-tumor liver tissues (p&lt;0.05). The number of metastatic liver tumors in the SDF-1 high expression group tended to be larger than that in the low expression group (p=0.12). Conclusions: The present data suggest that there is a significant association of the SDF-1/CXCR4 axis with enhanced liver metastasis and poor prognosis of the patients with colorectal liver metastasis. Furthermore, an enhanced expression of SDF-1 in non-tumor liver tissues may have an important role in the formation of liver metastasis.
Responses and Outcome Following Immunosuppressive Therapy in Large Granular Lymphocyte Leukemia-Associated Pure Red Cell Aplasia: A Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group.
Authors: Naohito Fujishima, Ken-ichi Sawada, Makoto Hirokawa, Kazuo Oshimi, Akira Matsuda, Masanao Teramura, Masamitsu Karasawa, Shinji Nakao, Akio Urabe, Mitsuhiro Omine, Keiya Ozawa
Journal: Blood (2007)
An open-label, dose-escalation phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO).
Authors: Hareth Nahi, Peter Hellemans, Tara J. Masterson, Pamela L. Clemens, Tahamtan Ahmadi, Jesus San Miguel, María-Victoria Mateos, Saad Zafar Usmani
Journal: Journal of Clinical Oncology (2016)

TPS8071 Background: Daratumumab (DARA), a human CD38 IgG1 monoclonal antibody, is approved in the US for patients with relapsed/refractory multiple myeloma (RR MM; ≥ 3 lines including a PI and IMiD or PI/IMiD double refractory). DARA has promising efficacy and a favorable safety profile as a monotherapy and in combination. The recommended DARA dose and schedule is 16 mg/kg intravenous (IV) weekly (QW) for 8 weeks, every 2 weeks (Q2W) for 16 weeks, and every 4 weeks (Q4W) thereafter. Subcutaneous (SC) formulations of therapeutic antibodies with recombinant human hyaluronidase (rHuPh20) have been approved in Europe. Here, SC DARA delivery combined with rHuPh20 is being evaluated. Methods: This is an ongoing phase 1b open-label, dose-escalation study of DARA given SC or IV in patients with symptomatic RR MM who have received ≥ 2 prior therapies. In Part 1, approximately 8 patients will enroll in each sequential cohort treated with doses of DARA-rHuPh20 SC (1200 mg-30,000 U; 1800 mg-45,000 U; subsequent doses to be determined) given QW in Cycles 1-2 (28 days/cycle), Q2W in Cycles 3-6, and Q4W thereafter. In the absence of dose limiting toxicity in > 2 patients in Cycle 1, patients will be assigned to the next dose cohort; up to 5 additional dose cohorts may be evaluated. A Study Evaluation Team will review pharmacokinetics (PK) and safety data to determine dose escalation and the recommended part 2 dose (RP2D). Part 2 will evaluate PK, safety, and efficacy of SC DARA. Approximately 80 patients will be randomized 1:1 to receive DARA-rHuPh20 SC at RP2D or DARA IV (1200 mg). The primary endpoints are serum trough concentrations of DARA just prior to Cycle 3 Day 1 and clinical safety. All patients will be observed for ≥ 72 hours and ≥ 24 hours, respectively, after the first SC infusion and, if necessary, after subsequent doses. To prevent/manage infusion-related reactions, pre- and post-infusion medications (steroids, paracetamol, montelukast, and antihistamines) similar to those administered with IV DARA will be given. Approximately 128 patients will be enrolled at 12 sites in 6 countries. The first patient was enrolled in October 2015. Clinical trial information: NCT02519452.
Abstract #5658: GITR and OX40 agonists initiate a biphasic Tcell response to mediate rejection of well-established tumors
Authors: Angela Pardee, Alan Epstein, Amy Wesa, Walter Storkus
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

T cell dysfunction, a hallmark of tumor immune escape, can be attributed to the manipulation of protective self-tolerance mechanisms by progressing tumors. Immune-stimulating reagents, such as those targeting costimulatory TNF receptors, are currently being designed to restore the function of pre-existing tumoricidal T cells and thus exhibit tremendous potential for the treatment of cancer. GITR and OX40 are costimulatory members of the TNF receptor family and are important regulators of T cell-mediated immunity. Using novel agonist agents, we are investigating the molecular, cellular, and treatment-associated consequences of GITR and OX40 engagement in the cancer setting. Remarkably, administration of either GITR or OX40 agonists to mice bearing well-established, day 17 sarcomas induces complete tumor rejection in these animals, accompanied by the development of tumor-specific CD8+ T cell memory. High percentages of GITRhi/OX40+ T cells accumulate in the tumors, but not in the peripheral lymphoid organs of mice bearing advanced tumors, indicating that tumor infiltrating T cells (TIL) are initially the primary target of late-stage costimulatory treatment. Indeed, alterations in the transcriptional profile of TIL are observed early following treatment, characterized by the enhanced expression of factors associated with tumoricidal Type-1 immunity (i.e. T-bet and IFN\#947;). However, GITR and OX40 agonists also appear to generate a secondary, delayed response as evidenced by T cell expansion in the tumor-draining lymph nodes approximately seven days after initial treatment, followed soon after by accumulation of Type-1-polarized T cells in the tumor microenvironment. Collectively, this data suggests a model in which the first level effect of costimulatory treatment is on the Type-1 skewing of tumor-localized T cells. A \#8220;second wave\#8221; of tumoricidal T cell activity is then initiated by T cell expansion in the draining lymph node and recruitment of expanded effector cells into the tumor microenvironment. Mechanistic insight gained from these studies is expected to facilitate the design of novel combinational therapies incorporating GITR- and OX40-based agonists, while the therapeutic efficacy demonstrated by these reagents in a model of late-stage disease strongly support their application in human clinical trials.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5658.